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Abstract
Background: There is no international diagnostic agreement for gestational diabetes 
mellitus (GDM). In 2014, Australia adopted a new definition and testing procedure. 
Since then, significantly more women have been diagnosed with GDM but with little 
difference in health outcomes. We explored the priorities and preferences of women 
potentially impacted by a GDM diagnosis.
Method: We recruited 15 women from the Gold Coast, Australia, to participate in 
a pilot community jury (CJ). Over two days, the women deliberated on the follow-
ing: (a) which important consequences of a diagnosis of GDM should be considered 
when defining GDM?; (b) what should Australian health practitioners call the condi-
tion known as GDM?
Results: Eight women attended the pilot CJ, and their recommendations were a con-
sensus. Women were surprised that the level of risk for physical harms was low but 
emotional harms were high. The final ranking of important consequences (high to 
low) was as follows: women's negative emotions; management burden of GDM; over-
medicalized pregnancy; minimizing infant risks; improving lifestyle; and macrosomia. 
To describe the four different clinical states of GDM, the women chose three differ-
ent labels. One was GDM.
Conclusions: The women from this pilot CJ prioritized the consequences of a diag-
nosis of GDM differently from clinicians. The current glucose threshold for GDM in 
Australia is set at a cut-point for adverse risks including macrosomia and neonatal hy-
perinsulinaemia. Definitions and guideline panels often fail to ask the affected public 
about their values and preferences. Community voices impacted by health policies 
should be embedded in the decision-making process.
2  |     THOMAS eT Al.
1  | INTRODUC TION
Gestational diabetes mellitus (GDM) is a health condition diagnosed 
in pregnancy and associated with an increased risk of physical com-
plications for the mother (eg caesarean section, pre-eclampsia) and 
infant (eg macrosomia, shoulder dystocia).1 Women diagnosed with 
GDM have reported emotional and financial consequences such as 
self-blame and guilt,2,3 confusion over diet management4 and the 
expense of healthy eating.5 Other women reported the diagnosis 
as an opportunity to change their behaviours.6
The definition of GDM has a complex history. Definitions have 
used different theoretical premises (percentile range like most lab-
oratory tests, the same values as in the non-pregnant or risk based). 
Where a risk-based assessment has been used, over time the focus 
has shifted. For example, in 1964, O’Sullivan and Mahan7 originally 
defined it as a way of identifying those women at risk of develop-
ing type 2 diabetes, whereas a large international study known 
as the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) 
study1 in 2008 focused on foetal outcomes. In addition, the diag-
nostic test has varied8 from a 50 g glucose load 1-hour screening 
test, a 75 g 2-hour test and a 100 g 3-hour test. Recommendations 
were initially for screening only ‘high-risk’ pregnant women, but 
now include all women and diagnostic cut-points have varied over 
several decades.9
The varying cut-points arise because the risk of complications 
of gestational diabetes is on a continuum. The higher the mother's 
blood glucose level (BGL), the higher the risk of complications to her 
and her baby. The HAPO study1 aimed to find a cut-point in the con-
tinuum to guide decisions on where the BGL should be drawn to de-
fine GDM. Unfortunately, an obvious cut-point was not identified. 
Using the available HAPO data, the International Association of the 
Diabetes and Pregnancy Study Groups (IADSPG) consensus panel 
recommended a BGL threshold associated with the risk of adverse 
infant outcomes (such as risk of macrosomia, excess infant adiposity 
and neonatal hyperinsulinaemia).8 However, this change was con-
troversial, and there is a lack of international consensus about the 
appropriate threshold between normal and elevated blood glucose.
Two recent Australian studies10,11 compared the old GDM defi-
nition and testing regimen to the new. Sexton and colleagues10 in 
North Queensland reported an increase in GDM diagnoses from 
10% under the old GDM definition to 20% under the new definition 
and Cade et al11 in Melbourne from 6% to 10%. Despite significant 
increases in the number of women diagnosed with gestational dia-
betes, both studies reported negligible health benefits for mothers 
and babies. The Cade study11 also reported a substantial increase 
in health-care costs: a net cost increase for their hospital alone was 
over A$560,000 annually. Importantly, many (but not all, eg the 
Royal Australian College of General Practitioners) medical colleges 
in Australia adopted the IADSPG new threshold and testing regimen. 
Given the absence of consensus and the substantial increase in GDM 
diagnoses, we believe it is timely to explore the values and prefer-
ences of the women who may be directly impacted by the change in 
GDM diagnosis.
We conducted a citizen/community jury (CJ) to explore wom-
en's perspectives. A CJ is a form of deliberative democracy and 
aims to elicit an informed community perspective on important and 
often controversial topics. CJ participants are provided with expert 
presentations and opportunities to question the experts, engage 
in both facilitated and private deliberation and are asked to form a 
consensus or majority ‘verdict’ on the topic question. Community 
jury participants deliberate on questions requiring a decision that is 
both informed and ethically sensitive. CJs have been used success-
fully in research to elicit informed perspectives for several health 
policy issues, for example screening mammography,12 screening for 
prostate cancer,13 case finding for dementia,14 quantifying health 
preferences15 and more broadly in local governments.16,17 We 
asked the CJ participants to deliberate on two questions:
Question 1: In the jury's view, which important consequences of 
a diagnosis of GDM should be considered by the consensus panel 
when discussing the Australian definition of GDM?
Question 2: What should Australian health practitioners call the 
health condition currently known as GDM?
2  | METHOD
2.1 | Steering committee
We established a steering committee to plan both the community 
jury and a consensus panel meeting to discuss the definition of GDM 
in Australia. The steering committee included a general practitioner, 
two endocrinologists, a consumer representative and two research-
ers with CJ and qualitative experience. This committee determined 
the eligibility criteria of the CJ participants, drafted the CJ questions 
and considered the expert information necessary for the jurors to 
make recommendations.
2.2 | Participants
We recruited women from the Gold Coast region (Australia) and 
rural areas (identified via the Modified Monash Model18) within 
driving distance to the Gold Coast through Taverner Research, 
using social media advertisements and random generated landline 
and location sample drawn from SamplePages. CJ participants are 
sampled from the public most directly affected by the deliberation 
question; therefore, 15 women between age 30 and 45 years (me-
dian age of mothers for births registered in 2016 was 31 years19) 
were recruited. Women were eligible if they had had at least one 
pregnancy and self-reported no previous diagnosis of GDM. We 
excluded women who had been diagnosed with GDM, were unable 
to provide informed consent and were unable to speak or under-
stand English. A diagnosis of GDM impacts women in rural com-
munities disproportionately than women living in urban areas20; 
therefore, we requested two women to be recruited from rural 
areas.
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Once recruited, CJ participants were contacted by the research 
team and provided further information regarding organizational de-
tails of their attendance and informed consent documents to sign. 
CJ participants from urban areas were reimbursed $100 gift cards/d 
of the CJ. Women from rural areas were reimbursed $200/d and 
provided with overnight accommodation. Ethical approval was pro-
vided by the Bond University Human Research Ethics Committee 
(LC01914).
2.3 | Procedure
The CJ was conducted over two weekend days, 2 and 3 February 
2019, at Bond University (see Table 1 for schedule). All sessions, 
except for the private deliberation on Sunday, were facilitated by 
RT (a psychologist and experienced facilitator), who moderated dis-
cussions and ensured all jurors had equal opportunity to voice opin-
ions. Two researchers, AMS, RS and an observer from Therapeutic 
Guidelines, LAC, observed CJ processes and jurors’ engagement for 
the sessions except the private deliberation. Only CJ participants 
were present during private deliberation to maintain confidential-
ity and prevent bias. Participants provided written consent prior to 
participating.
Four presentations were conducted on Saturday (via voice-over 
PowerPoint) and followed with a telephone question and answer 
session with each presenter (descriptions of topics and experts are 
provided in Box 1). After the presentations, the CJ participants com-
pleted two activities (see below) to assist in answering the two jury 
questions.
On Sunday, CJ participants reconvened. Following a discussion 
about reflections from Saturday and overnight, participants were of-
fered the opportunity to further question presenters for additional 
information and clarification. CJ participants elected a representa-
tive to facilitate private deliberation and deliberated on the two CJ 
questions until consensus or impasse was reached. The CJ recom-
mendations were presented to the Chair of the Steering Committee 
Paul Glasziou and to the researchers and observers. At the conclu-
sion of the CJ, participants were provided opportunity to debrief on 
CJ processes and outcomes.
2.4 | Materials
2.4.1 | Presentations
Four experts provided presentations to the CJ participants. 
Presenters, their topics, a short biography and their presentation 
URLs are provided in Box 1. Participants were provided with biogra-
phies of the presenters and copies of PowerPoint presentations. No 
reimbursement (financial or otherwise) was provided to the experts.
2.4.2 | Activity 1: Ranking the 
consequences of GDM
The Steering Committee identified physical and emotional conse-
quences often reported in GDM as important for the CJ partici-
pants. To quantify the physical consequences (eg pre-term birth, 
caesarean section, macrosomia, shoulder dystocia), we used risk 
ratios identified by McIntyre et al21 to construct icon arrays for 
CJ participants. We conducted a systematic review of qualitative 
data22 to identify reports of emotional consequences. Twelve iden-
tified consequences were described on A4 size laminated paper 
and were presented and explained to the CJ participants. A fur-
ther four blank consequence pages were also provided. A smaller 
version of each consequence and its description is provided in 
Supplementary File S1.
On Day 1, CJ participants individually ranked the consequences 
on a worksheet. The group then discussed their rankings and their 
reasons which were documented on a whiteboard. On day 2, the par-
ticipants discussed their rankings again and deliberated in private.
TA B L E  1   Schedule of events
Saturday 2nd February
9.00 Welcome, introductions, orientation 
to the CJ
Why are we here?
Rae Thomas
9.45 What is gestational diabetes 
mellitus, how is it diagnosed, and 
what are the treatment options
David McIntyre
10.15 Q&A with David  
10.30 MORNING TEA  
10.45 A brief history of GDM definitions Julia Lowe
11.15 Q&A with Julia  
11.30 The Australian context Clare Heal
11.45 Q&A with Clare  
12.00 The potential consequences of a 
GDM diagnosis
Leah Hardiman
12.20 Q&A with Leah  
12.30 LUNCH  
1.00 Activity 1, 2  
3.00 End  
Sunday 3rd February
9.00 Check-in, reflections, orientation 
to today
Rae Thomas
9.30 Contact Experts Rae Thomas
10.00 Activity 1 and 2 revisited Rae Thomas
10.30 MORNING TEA  
Flexible 
timing
Deliberation  
LUNCH  
Present recommendations to Paul 
Glasziou (Chair of the steering 
committee and member of the 
consensus panel)
Paul Glasziou
3.00 End  
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2.4.3 | Activity 2: Considering the labelling of GDM
The facilitator (RT) presented a PowerPoint presentation of four sce-
narios representing four different clinical states/descriptions of how 
women might receive a diagnosis of GDM. The scenarios included 
a short story about a woman and a description of how she met the 
current Australian criteria for GDM. See supplementary File S2 for 
full example details.
The descriptions were as follows:
A Katie: developed diabetes as a result of pregnancy (ie this woman 
now met the criteria for non-pregnant diabetes);
B Jenny: has higher than usual blood sugar levels as a result of the 
pregnancy and is at increased risk of complications;
C Emily: has higher than usual blood sugar levels as a result of the 
pregnancy and is at normal risk of complications; and
D Sofia: had diabetes before pregnancy and still has diabetes in 
pregnancy.
The risk of complications was deliberately varied in scenarios B 
and C to examine its impact on the label. See Supplementary File S2 
for clinical descriptions provided to the CJ participants.
Participants were given scenarios and a list of the potential labels 
with two blank options describing the four different clinical states. 
The descriptors and the labels were developed in consultation with 
the Steering Committee, GPs and research colleagues.
On day 1, CJ participants were asked to identify their preferred 
label for each of the scenarios A–D followed by a discussion about 
reasons. CJ participants were asked to individually post each label 
to a laminated vignette which had been arranged on a wall. All labels 
had to be used, either with a vignette description or in a personal 
‘discarded’ pile. Participants could also develop alternative labels. 
On day 2, CJ participants deliberated in private.
2.5 | Statistical analysis
CJ recommendations were recorded on the whiteboard, and evidence 
of ranking and labelling was visually displayed and photographed. CJ 
proceedings were audio-recorded and transcribed. CJ participant's 
recommendations to each question were presented at the end of day 
2 and are provided verbatim. Two sections of the transcripts were 
qualitatively analysed to identify potential reasons for their recom-
mendations (overnight reflections and private deliberations).
3  | RESULTS
Taverner Research contacted 116 women for 15 to agree to partici-
pate (73 urban, 43 rural). Of the 15 women recruited, eight attended 
the CJ weekend: three failed to confirm attendance on the Friday 
before the CJ and failed to attend; three confirmed participants 
failed to attend without explanation; and one participant was unable 
to attend due to personal illness. One of the participants who did 
not attend was from a rural area. The participants’ mean age was 
38 years; seven were married/defacto and one separated; all had 
children (1 with 1; 4 with 2; 3 with 3); four were born in Australia, 
two in New Zealand, one in the USA and one in the Philippines; one 
lived rurally and seven regionally.
3.1 | Jury recommendations and potential reasons
3.1.1 | Question 1
In the jury's view, which important consequences of a diagnosis of 
GDM should be considered by the consensus panel when discussing the 
Australian definition of GDM?
CJ recommendation
The CJ participants grouped together some of the 12 conse-
quences identified from the systematic review as they considered 
this best reflected their content. For example, the consequence 
labelled ‘burden of managing GDM’ also incorporated ‘dietary 
management-related stress’ and ‘increased medical appointments’. 
Therefore, the list of 12 consequences was reduced to six. The 
women ranked the new groups of consequences that they consid-
ered the most important to women, from highest priority to lowest 
(see Box 2).
BOX 1 Expert presentations and download links
1. What is gestational diabetes mellitus, how is it diag-
nosed and what are the treatment options?
Professor David McIntyre is an expert in obstetric medi-
cine and a current Board member of the Australasian 
Diabetes in Pregnancy Society. He was a co-author on 
the HAPO study.1
2. A brief history of gestational diabetes mellitus definitions
Associate Professor Julia Lowe is an endocrinologist work-
ing clinically with pregnant women. She was a co-author 
on the HAPO study.1Professor Clare Heal is a general 
practitioner and researcher in rural Australia. She co-
authored an Australian publication of the prevalence 
and health outcomes of women diagnosed with GDM.10
3. The potential consequences of a gestational diabetes 
mellitus diagnosis
Leah Hardiman is a consumer representative and the past 
President of Maternity Choices Australia and repre-
sents women's experiences on national committees.All 
presentations can be viewed at: https ://osf.io/mqd3c/ 
?view_only=502b1 cf9ef 014e3 589cb 39b5d 6c9d81b
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The CJ participants concluded that:
P4: We felt collectively that the most significant conse-
quence of being diagnosed, being told you've got a diag-
nosis for women was the negative emotions that go with 
that, the guilt and the - everything, self-blame and sadness 
and dread and all that, expectation and all of that. We felt 
collectively that that was the number one consequence. 
(day 2 page 131)
The women did not identify any additional consequences to in-
clude than those synthesized from the available evidence.
Potential reasons from reflections and deliberations
At the start of day 1, the women had individually ranked the poten-
tial consequences of GDM on day 1, most women (5/8) ranked the 
baby's well-being as top priority (eg ‘opportunity to minimize risks to 
unborn baby’):
P2: It's all about the baby
RT: …. Tell me what you mean by it's all about the baby?
P2: Make sure that baby is safe
PX: It's healthy. 
(day 1 page 58)
On day 1, the consequences related to the woman's well-being (eg 
negative emotions such as self-blame, sadness and anxiety) stemming 
from being diagnosed with GDM were a lower priority. However, views 
differed:
P6: I think all about the baby is just a kneejerk reaction. 
(day 1 page 58)
and a rigorous discussion followed about potential risks to mother 
and baby.
At the start of day 2, most CJ women reconsidered their original 
position on the consequences of a GDM diagnosis as a result of re-
flection and discussions with friends and family, for example:
P6: I talked to my husband about it last night and I spoke 
to my sister who's a midwife and texted my - the couple 
of friends I mentioned who had gestational diabetes and 
yeah, just reflected on it, I suppose…. I felt like I did have 
insights, yeah…. I don't quite know how to word it, basi-
cally the risks of gestational diabetes are a lot less than I 
previously thought. 
(day 2 page 1)
P7: I had just a quick chat about it with my husband about 
it yesterday, just explain what we did, but we didn't really 
talk about it too much, but had it swirling around in my 
head trying to grapple with the 12, ordering the 12 most 
important and I had sort of negative emotions at num-
ber three and I think that is definitely moving up, but I'm 
still grappling with the numbers of risks for birth injury 
and that sort of thing… maybe those numbers [eg around 
birth injury] don't really matter because there's still such 
a small risk. So that's just what I've been thinking for the 
past 12 hours. 
(day 2 page 8)
Other women changed their minds after reflecting on the evidence 
that was presented by the experts on day 1 of the Community Jury.
P2: I kind of went from more focused on the minimised 
risk [to the baby], because obviously we didn't have the 
numbers in front of us… But now knowing that the risks 
are quite minimal in terms of numbers, …. the focus is 
more about the woman's wellbeing, her stress, her men-
tal health… and we saw a few yesterday after that whole 
risk thing. We were like, oh okay, yeah, the risk is minimal, 
so I think there was a few of us going, our minds have 
turned a bit, because I know for me now it is, yeah, kind 
of pretty much flipped. 
(day 2 page 2)
The women also articulated the distinction between the instinctive 
and emotional and more deliberative thinking processes.
P4: Well our first reaction's always an emotional one, 
isn't it; we don't automatically look for numbers, we au-
tomatically react emotionally. 
(day 2 page 133)
The women recognized that because their views were based on 
evidence presented by the experts on day 1, they would likely differ 
from those unfamiliar with the evidence.
P2: So we are thinking from the point of view that we 
know all the information and that's why we're putting 
that ‘risk to baby’ down at number five… But someone 
who doesn't know that information, like we have, that's 
going to be quite high actually….
P6: That's why we're an informed community jury 
though, because we do know the numbers, we know that 
that's what makes it bump down. 
(day 2 page 105)
More specifically, having learned, for example that the increase 
in risks that are associated with a GDM diagnosis, is small for many 
outcomes, led to the women to consider that a diagnosis of GDM 
may not be helpful—and possibly even harmful—to some pregnant 
women:
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P7: … that's something we need to really think about, 
that women that may have been fine without it [GDM di-
agnosis] may have been teetering on the edge of anxiety 
and that sort of thing.
P4: And maybe fine through the whole pregnancy. If they 
were at the very low end…
P7: Right, exactly
P4: …then there might be no - there might be zero 
consequences. 
(day 2 page 82)
Similarly, having learned that the risks of a caesarean section dif-
fered between the diagnosed (24/100) and not-diagnosed (17/100) 
women by only 7/100, also led the jurors to change their minds on its 
relative importance.
P1: I don't even think they should be F***ing told about 
the caesarean. I think it's…
P4: But the doctors have to tell them, it's a potential risk
P1: But that's what I'm saying, she said you can take 
them out. There's 100 potential risks and [Participant 7] 
has read it and it was no different, was it?
P7: No, there was actually a drop in the incidence of 
emergency caesareans in one study
P4: But you're right, we agree that them saying that 
they might have to have a C-section is like putting the 
cast on a bruise, it's just a fearmongering things, it's 
just in case. 
(day 2 page 104)
3.1.2 | Question 2
What should Australian health practitioners call the health condition 
currently known as GDM?
CJ recommendation
The women's final recommendations and their reasoning for what to 
label the four different clinical states of GDM is described in Box 3 
from most preferred to least preferred for each descriptor. The women 
did not identify any other potential labels for GDM than those sug-
gested and provided by the Steering Committee and clinical and re-
search colleagues.
Potential reasons from reflections and deliberations
Some CJ participants reported overnight ruminations about the 
label GDM. For example,
P4: It's not labelled as a disease, but it feels like a disease, 
it's treated as a disease when it's a risk. 
(day 2 page 5)
P5: …. I just sort of like thinking about all the definitions and 
even the terminologies used or just referring to it as gesta-
tional and diabetes, I thought with the definition and the 
risk, it shouldn't even be called that. Like because for some-
one who is not - who's never had diabetes or a new mum, 
it's pretty confronting, I thought, to be told that you've got 
it because you know that is a chronic illness …… 
(day 2 page 8)
Decisions on what to label the different clinical states of women 
diagnosed with GDM centred around balancing the emotional harms 
following a GDM diagnosis and providing women with a label that 
informed her of the seriousness of her raised blood sugar level. The 
women differentiated between the different clinical scenarios and 
grappled with labelling them all as GDM.
P4: Yes, so that's - would you say what she's got, would 
you define - if Jenny [scenario B] and Katie [scenario A], 
came in on the same day, would you tell Jenny the same 
thing that you would tell Katie?
P2: No
P4: So that's where we can't label them the same
They were more nuanced in their terminology and considerations 
of diagnostic impact than the current definition allows,
P7: Why wouldn't we just call this one gestational diabe-
tes as it stands now?
P6: Yeah, I would, yeah
P7: Because I think the issue with the consequences of 
telling a woman that falls at the really low end of the 
spectrum, the consequences for her [one scenario] are 
significantly more than her [another scenario] because 
she needs to manage her condition…
[…]
BOX 2 CJ participants’ ranking of important 
consequences
1. Negative emotions such as self-blame, sadness and 
anxiety
2. The burden of managing GDM (including dietary man-
agement stress and increased medical appointments).
3. Over-medicalized pregnancy (including caesarean 
sections)
4. The opportunity to minimize the risks to the baby (in-
cluding shoulder dystocia or birth injury and pre-term 
birth).
5. The opportunity to improve lifestyle (including reducing 
a women's risk of developing diabetes after pregnancy)
6. Having a ‘big’ baby
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P7: She needs the lower - you don't need to jab yourself, 
we're not going to book you straight in for an induction 
and C-section, but you need to be careful…
P2: Yeah
P7: …and monitor your blood sugars and we'll mon-
itor you, maybe you'll have two extra appointments 
that a regular, normal, less risk, this lady's going 
to have six, somewhere in between and split the 
condition… 
(day 2 page 119 – 120)
and maybe more cautious,
P4: Poor all Katie [scenario A], sorry love
P5: We've just diagnosed you. 
(day 2 page 120)
The two scenarios with higher than usual blood sugar but differ-
ent risks of complications (scenarios B and C) had the most discussion 
and the most concern about unnecessary harms. For example, when 
discussing the scenario depicting raised blood sugar with normal risk 
(scenario C), the women deliberated:
P4: Emily [scenario C] has higher than usual blood sugar 
levels as a result of the pregnancy and is at normal risk of 
complications. So she's never had it before, she's eating 
too much Baskin, how do we define her? Do we tell her 
she's diabetic, do we tell her she's…
P2: Well I think most things up there [potential labels 
posted on scenarios by women earlier] are related to 
blood sugar and pregnancy, so if we go by…
P4: So how do we label, because our job is to label what 
she's got
BOX 3 CJ participants’ preferred labels to describe the differing clinical states of GDM (in descending preference)
A Katie: developed diabetes as a result of pregnancy (ie now meets non-pregnant diabetes criteria)
Gestational diabetes (most preferred)
Pregnancy induced diabetes
Diabetes in pregnancy
Diabetes due to pregnancy (least preferred)
P4: We're labelling Katie because we want her to have all the information and full assistance and make sure she knows exactly what she needs 
to do and go to the extra appointments and all the rest of it. And we didn’t know whether the outcome after her pregnancy would still be 
diabetes, we weren't 100 per cent sure, so we listed it this way, gestational, we thought we'd label her with gestational, pregnancy induced, 
diabetes in pregnancy and diabetes due to pregnancy. (day 2 page 136)
B. Jenny: has higher than usual blood sugar levels as a result of the pregnancy and is at increased risk of complications
Raised blood sugar in pregnancy (most preferred)
Reduced tolerance to raised blood sugar in pregnancy
Altered glucose metabolism in pregnancy (least preferred)
P4: So we decided that Jenny doesn't need to be told that she's got gestational diabetes because it would scare her to death and it's not nec-
essary. We decided that we would label Jenny as having raised blood sugar in pregnancy, so that she's aware, she can do what she needs 
to do, but she's not panicking, she's not needing to go to 100 appointments and change too much significantly, be aware and make the 
necessary changes, et cetera.(day 2 page 136)
C. Emily: has higher than usual blood sugar levels as a result of the pregnancy and is at normal risk of complications
Raised blood sugar in pregnancy (most preferred)
Pregnant
Reduced tolerance to raised blood sugar in pregnancy (least preferred)
P4: …. we like Emily and we decided to also not label her as having gestational diabetes because we don’t think it's necessary, based on our 
list of consequences, we're trying not to freak her out, so we're going to tell her she's got raised blood sugar and give her all the information 
and try and get her through it that way without needing all that extra stuff. (day 2 page 137)
D. Sofia: had diabetes before pregnancy and still has diabetes in pregnancy
Diabetes (most preferred)
Diabetes in pregnancy
Gestational diabetes
Hyperglycaemia in pregnancy (least preferred)P4:…. so she's diabetic. So we started this one first and got a bit excited, she's diabetic. She's 
also pregnant. She's got diabetes and pregnancy, gestational, so this was our list. (day2 page137)
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P2: I would tell her she - I'd just tell her she's pregnant. I 
wouldn't tell her anything else
P4: So do we tell her she's - so raised blood sugar and 
hyperglycaemia, is that not the same thing but one's a 
scary… 
(day 2 page 109)
While for scenario B with increased risk,
P7: But she's at - she is at an increased risk of 
complications
[…]
P4: Keeping in mind what the complications are, which 
are minimal, how do we - what do we - how do we define 
her?
P2: Leave her alone….
[Laughter]
P6: Yeah, I say that we go raised blood sugar in pregnancy 
for her
[…]
P4: So we're just going to warn her that this is happening, 
if you continue this way, this is going to be the outcome… 
……..So reduced tolerance to raised blood sugar, would 
that be - yeah? So we're not going to tell her she's got 
pregnancy induced diabetes, that's down the bottom, 
right?
P6: Then I think we should get rid of diabetes limited to 
pregnancy and pregnancy induced diabetes for Jenny 
[scenario B]
PX: Me too
P4: Because we don't want to stress out poor Jenny [sce-
nario B]
However, they recognized that increased risk may need further 
monitoring.
P7: I wouldn't want to be labelled as gestational diabetes, 
but I would want to know and I'd want a couple of extra 
checks, just to make sure everything's going okay
P6: I think you'd get that if you had raised blood sugar in 
pregnancy
P2: They would keep an eye on it, yeah
P6: Yeah
P4: You would get the same outcomes, but without the 
label and the stress
4  | DISCUSSION
While the participants in our pilot community jury initially agreed 
that the most important consequence of a GDM diagnosis (rated as 
highest priority) was the ‘opportunity to minimize the risks to the 
unborn baby’, after reviewing the level of risks and upon reflection, 
the women changed their opinions and countered the ‘knee jerk’ 
(day 2 pg 133) reaction they believe they had on day 1. After private 
deliberation, the women rated the most important consequence 
of a diagnosis of GDM to be the negative emotional state of the 
mother. The priority placed on this consequence over the physical 
consequences preferenced by the HAPO study,1 and subsequent 
definition GDM potentially suggests a significant pivot away from 
traditional clinical thinking.
Also challenging the traditional nomenclature of clinicians, the 
CJ participants grappled with what labels to ascribe the four dif-
ferent clinical states of GDM (all currently labelled as ‘GDM’). They 
recognized that the different clinical states warranted different la-
bels to signal appropriate risks while mitigating unnecessary stress 
and burden on diagnosed women, which is reflected in the various 
labels they suggested for scenarios depicting different levels of 
GDM risk.
The women of this CJ clearly understood the numerical relative 
risks of physical consequences and the qualitative risks and benefits 
of other women's lived experiences. When informed of the potential 
risks and benefits of a diagnosis of GDM, women prioritize these 
consequences differently from clinicians. They also understood the 
different clinical states of GDM and concluded they differed suffi-
ciently to warrant different ‘labels’. This pilot CJ had a small sample 
of women and should be repeated to explore whether women in 
other areas have similar or divergent views. However, the voices of 
informed, affected publics are often missing from panels that define 
health conditions and may differ from those of the clinicians. Their 
voices, preferences and opinions should be embedded in the deci-
sion-making process.
We strengthened our methods by standardizing expert pre-
sentations as voice-over PowerPoint to minimize presenter bias 
and providing hyperlinks to these in the article for transparency. A 
steering committee was established to develop the CJ questions, 
and members of this group conducted the presentations. Although 
a small sample, we included the voices of rural and regional women. 
As the women were all from South East Queensland, Australia, 
women from other regions might have different responses. We also 
represented the evidence of consequences of GDM by developing 
infographics of published and aggregated data1,22 but recognize 
that women relied on this evidence to form their recommendations, 
and these may be different if other evidence were presented.
The adverse risk of perinatal outcomes used in the HAPO 
study1 underpinned the change in blood glucose levels used to di-
agnose GDM in some countries, such as Australia where the defini-
tion of GDM was changed in 2014. However, this change has been 
contentious, as since the change, some studies have reported in-
creasing prevalence of GDM but few improvements in health out-
comes.10,11 Moreover, many women report emotional and financial 
challenges when diagnosed with GDM.22 As a risk factor, higher 
levels of hyperglycaemia are associated with increases the risk of 
post-partum type 2 diabetes and cardiovascular disease, as well as 
increasing in the risk of adverse perinatal outcomes. However, the 
current definition of GDM in Australia is not stratified for risk and 
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the women diagnosed with GDM (irrespective of risk) are treated 
similarly.
Our findings lend support to a reconsideration of GDM thresh-
old definition in Australia and what different clinical states might be 
called. However, these finding should be interpreted in the context 
of deliberative methods and their strengths and limitations. CJs are 
small by design,12-15 and this has sometimes been criticized. A scop-
ing review of public deliberative techniques in health revealed CJs 
were the most common technique and ranged in size from 9 to 16 
people.23 However, we had fewer participants than we anticipated, 
and the findings should be interpreted cautiously. We cannot claim 
that women's views from this CJ represent broader community 
views. Because we wanted to recruit the population most affected 
by the question of GDM definition, we recruited mothers, who are 
challenging to recruit as they experience many competing demands 
on their time. When contacted, many women could not attend the 
required 2 days, and some had sick children during the CJ weekend. 
Recruitment limitations from this study serve as key learnings, and 
future CJs on GDM will be adapted to suit the demands of young 
families. For example, for young mothers, it may be more prudent 
to conduct CJs on weekdays when childcare may be more acces-
sible or conduct the CJ over multiple days/weeks (1 day a week 
for 2 weeks). Despite recruitment challenges, the women who did 
attend produced consensus recommendations and transcripts re-
flecting cohesive group discussion and no dissention. However, we 
upheld robust CJ methods. We recruited from the population we 
considered most affected by the question, and the jury verdict was 
unanimous.
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